Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DSGN Stock Forecast 2025-2026
$9.78
Current Price
$556.54M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DSGN Price Targets
+53.4%
To High Target of $15.00
+38.0%
To Median Target of $13.50
+22.7%
To Low Target of $12.00
DSGN Price Momentum
+4.2%
1 Week Change
+29.4%
1 Month Change
+52.6%
1 Year Change
+58.5%
Year-to-Date Change
-5.1%
From 52W High of $10.31
+276.2%
From 52W Low of $2.60
📊 TOP ANALYST CALLS
Did DSGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Design Therapeutics is one of their latest high-conviction picks.
Latest DSGN Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, DSGN has a bullish consensus with a median price target of $13.50 (ranging from $12.00 to $15.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $9.78, the median forecast implies a 38.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Yasmeen Rahimi at Piper Sandler, suggesting a 22.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DSGN Analyst Ratings
4
Buy
0
Hold
0
Sell
DSGN Price Target Range
Low
$12.00
Average
$13.50
High
$15.00
Current: $9.78
Latest DSGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DSGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2025 | Leerink Partners | Joseph Schwartz | Outperform | Upgrade | $14.00 |
| Nov 20, 2025 | RBC Capital | Leonid Timashev | Outperform | Upgrade | $13.00 |
| Nov 6, 2025 | RBC Capital | Leonid Timashev | Sector Perform | Maintains | $6.00 |
| Aug 6, 2024 | RBC Capital | Leonid Timashev | Sector Perform | Reiterates | $4.00 |
| May 7, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Upgrade | $12.00 |
| Mar 20, 2024 | RBC Capital | Leonid Timashev | Sector Perform | Reiterates | $4.00 |
| Mar 20, 2024 | Wedbush | Laura Chico | Neutral | Reiterates | $5.00 |
| Nov 14, 2023 | RBC Capital | Leonid Timashev | Sector Perform | Maintains | $4.00 |
| Aug 15, 2023 | RBC Capital | Leonid Timashev | Sector Perform | Downgrade | $7.00 |
| Aug 15, 2023 | SVB Leerink | Joseph Schwartz | Market Perform | Downgrade | $6.00 |
| Aug 15, 2023 | Wedbush | Laura Chico | Neutral | Downgrade | $6.00 |
| May 10, 2023 | Wedbush | Laura Chico | Outperform | Maintains | $19.00 |
| May 10, 2023 | RBC Capital | Leonid Timashev | Outperform | Maintains | $23.00 |
| May 4, 2023 | Goldman Sachs | Madhu Kumar | Neutral | Upgrade | $N/A |
| Mar 15, 2023 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $24.00 |
| Dec 9, 2022 | SVB Leerink | Joseph Schwartz | Outperform | Maintains | $22.00 |
| Dec 8, 2022 | RBC Capital | Leonid Timashev | Outperform | Maintains | $24.00 |
| Aug 26, 2022 | RBC Capital | Outperform | Initiates | $N/A | |
| Aug 9, 2022 | Wedbush | Laura Chico | Outperform | Maintains | $26.00 |
| Jun 10, 2022 | Wedbush | Outperform | Initiates | $N/A |
Design Therapeutics, Inc. (DSGN) Competitors
The following stocks are similar to Design Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DSGN
Design Therapeutics
mkt cap
556.54M
Design Therapeutics, Inc. (DSGN) Financial Data
Design Therapeutics, Inc. has a market capitalization of $556.54M with a P/E ratio of -11.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -29.8%.
Valuation Metrics
Market Cap
$556.54M
Enterprise Value
$352.31M
P/E Ratio
-11.1x
PEG Ratio
-0.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+37.0%
Current Ratio
18.7x
Debt/Equity
0.9x
ROE
-29.8%
ROA
-20.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Design Therapeutics, Inc. (DSGN) Business Model
About Design Therapeutics, Inc.
What They Do
Develops treatments for serious degenerative disorders.
Business Model
The company utilizes a proprietary technology platform to create GeneTAC™ molecules that target dysfunctional genes. By focusing on inherited diseases associated with gene expression dysregulation, it aims to offer innovative therapeutic options where few exist, primarily generating revenue through partnerships and potential product sales in the health sector.
Additional Information
Design Therapeutics is dedicated to bridging genetic research with clinical applications, focusing on rare genetic and neurological diseases. Its efforts contribute to the advancement of personalized medicine and biotechnology solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
55
CEO
Mr. Pratik Shah Ph.D.
Country
United States
IPO Year
2021
Website
www.designtx.comDesign Therapeutics, Inc. (DSGN) Latest News & Analysis
Latest News
Quick Summary
Design Therapeutics, Inc. (Nasdaq: DSGN) will participate in fireside chats at upcoming investor conferences, focusing on treatments for serious degenerative genetic diseases.
Why It Matters
Design Therapeutics' participation in investor conferences signals potential growth and transparency, which can boost investor confidence and interest in the stock.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NVIDIA Inc. (NASDAQ: NVDA) reported strong fiscal Q3 results and provided positive forward guidance, leading to higher futures trading, though it fell slightly short of Wall Street expectations.
Why It Matters
NVIDIA's strong earnings and guidance increase investor confidence in tech stocks, influencing market trends and potentially driving up stock prices in the sector.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Design Therapeutics received ex-US regulatory clearance for DT-818, targeting Myotonic Dystrophy Type-1. Ongoing trials for DT-216 and DT-168 continue, with $206M in cash and securities reported.
Why It Matters
Regulatory clearance boosts Design Therapeutics' credibility and market potential for DT-818, enhancing investor confidence. Strong cash reserves support ongoing clinical trials, promising future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Design Therapeutics, Inc. has appointed Justin Gover to its Board of Directors, effective immediately. The company focuses on treatments for degenerative genetic diseases.
Why It Matters
Justin Gover's appointment to Design Therapeutics' Board could enhance strategic direction and credibility, potentially impacting the company's growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript
3 months ago
Quick Summary
Design Therapeutics, Inc. (NASDAQ: DSGN) will present at the Cantor Global Healthcare Conference on September 4, 2025, featuring CEO Pratik Shah.
Why It Matters
Design Therapeutics' participation in the Cantor Global Healthcare Conference signals potential insights on its pipeline and strategy, impacting investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Design Therapeutics, Inc. (Nasdaq: DSGN) will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 4, 2025, at 10:55 a.m. ET in New York.
Why It Matters
Design Therapeutics' participation in a major healthcare conference highlights its visibility and potential, influencing investor sentiment and stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DSGN Stock
What is Design Therapeutics, Inc.'s (DSGN) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Design Therapeutics, Inc. (DSGN) has a median price target of $13.50. The highest price target is $15.00 and the lowest is $12.00.
Is DSGN stock a good investment in 2026?
According to current analyst ratings, DSGN has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DSGN stock?
Wall Street analysts predict DSGN stock could reach $13.50 in the next 12 months. This represents a 38.0% increase from the current price of $9.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Design Therapeutics, Inc.'s business model?
The company utilizes a proprietary technology platform to create GeneTAC™ molecules that target dysfunctional genes. By focusing on inherited diseases associated with gene expression dysregulation, it aims to offer innovative therapeutic options where few exist, primarily generating revenue through partnerships and potential product sales in the health sector.
What is the highest forecasted price for DSGN Design Therapeutics, Inc.?
The highest price target for DSGN is $15.00 from at , which represents a 53.4% increase from the current price of $9.78.
What is the lowest forecasted price for DSGN Design Therapeutics, Inc.?
The lowest price target for DSGN is $12.00 from Yasmeen Rahimi at Piper Sandler, which represents a 22.7% increase from the current price of $9.78.
What is the overall DSGN consensus from analysts for Design Therapeutics, Inc.?
The overall analyst consensus for DSGN is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.50.
How accurate are DSGN stock price projections?
Stock price projections, including those for Design Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 7:22 AM UTC